Intermittent parathyroid hormone therapy to increase bone formation

Joint Bone Spine

Volumn 73, Issue 3, 2006, Pages 262-269

  Thomas, Thierry ^a  

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

Author keywords

Osteoporosis; Parathyroid hormone; Teriparatide

Indexed keywords

PARATHYROID HORMONE;

BONE DENSITY; CELL CULTURE; CLINICAL TRIAL; DISEASE ASSOCIATION; HUMAN; NONHUMAN; OSSIFICATION; OSTEOPOROSIS; POROSITY; SHORT SURVEY; TRABECULAR BONE;

ANIMALS; BONE AND BONES; BONE DENSITY; BONE RESORPTION; CELLS, CULTURED; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; OSTEOGENESIS; OSTEOPOROSIS; PARATHYROID HORMONE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33646030271     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2005.11.007     Document Type: Short Survey

References (76)

1. Selye H. On the stimulation of new bone formation with parathyroid extract and irradiated ergosterol. Endocrinology 16 (1932) 547-558
2. Rubin M.R., Cosman F., Lindsay R., and Bilezikian J.P. The anabolic effects of parathyroid hormone. Osteoporos. Int. 13 (2002) 267-277
3. Silverberg S.J., Shane E., de la Cruz L., Dempster D.W., Feldman F., Seldin D., et al. Skeletal disease in primary hyperparathyroidism. J. Bone Miner. Res. 4 (1989) 283-291
4. Dempster D.W., Cosman F., Parisien M., Shen V., and Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr. Rev. 14 (1993) 690-709
5. Parisien M., Silverberg S.J., Shane E., de la Cruz L., Lindsay R., Bilezikian J.P., et al. The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. J. Clin. Endocrinol. Metab. 70 (1990) 930-938
6. Parisien M., Mellish R.W., Silverberg S.J., Shane E., Lindsay R., Bilezikian J.P., et al. Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular strut analysis. J. Bone Miner. Res. 7 (1992) 913-919
7. Wilson R.J., Rao S., Ellis B., Kleerekoper M., and Parfitt A.M. Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures. Ann. Intern. Med. 109 (1988) 959-962
8. Khosla S., Melton III L.J., Wermers R.A., Crowson C.S., O'Fallon W., and Riggs B. Primary hyperparathyroidism and the risk of fracture: a population-based study. J. Bone Miner. Res. 14 (1999) 1700-1707
9. Langdahl B.L., Mortensen L., Vesterby A., Eriksen E.F., and Charles P. Bone histomorphometry in hypoparathyroid patients treated with vitamin D. Bone 18 (1996) 103-108
10. Juppner H., Abou-Samra A.B., Freeman M., Kong X.F., Schipani E., Richards J., et al. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 254 (1991) 1024-1026
11. Usdin T.B., Gruber C., and Bonner T.I. Identification and functional expression of a receptor selectively recognizing parathyroid hormone, the PTH2 receptor. J. Biol. Chem. 270 (1995) 15455-15458
12. Eriksen E.F., Colvard D.S., Berg N.J., Graham M.L., Mann K.G., Spelsberg T.C., et al. Evidence of estrogen receptors in normal human osteoblast-like cells. Science 241 (1988) 84-86
13. Fujita T., Meguro T., Fukuyama R., Nakamuta H., and Koida M. New signaling pathway for parathyroid hormone and cyclic AMP action on extracellular-regulated kinase and cell proliferation in bone cells. Checkpoint of modulation by cyclic AMP. J. Biol. Chem. 277 (2002) 22191-22200
14. Canalis E., Centrella M., Burch W., and McCarthy T.L. Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. J. Clin. Invest. 83 (1989) 60-65
15. Hock J.M. Anabolic PTH targets proliferating cells of the primary spongiosa in young rats and increases the number differentiating into osteoblasts. J. Bone Miner. Res. 9 Suppl 1 (1994) 5421
16. Onyia J.E., Miller B., Hulman J., Liang J., Galvin R., Frolik C., et al. Proliferating cells in the primary spongiosa express osteoblastic phenotype in vitro. Bone 20 (1997) 93-100
17. Dobnig H., and Turner R.T. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 136 (1995) 3632-3638
18. Jilka R.L., Gubrij A., Ali A., Wynne R.A., Weinstein R.S., O'Brien A., et al. Ablation of osteoblasts, but not lining cells, in 3.6Col1a1-tk transgenic mice prevents the anabolic effect of intermittent PTH: evidence against the lining cell activation hypothesis. J. Bone Miner Res. 19 Suppl 1 (2004) S105
19. Jilka R.L., Weinstein R.S., Bellido T., Roberson P., Parfitt A.M., and Manolagas S.C. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J. Clin. Invest. 104 (1999) 439-446
20. Chen H.L., Demiralp B., Schneider A., Koh A.J., Silve C., Wang C.Y., et al. Parathyroid hormone and parathyroid hormone-related protein exert both pro- and anti-apoptotic effects in mesenchymal cells. J. Biol. Chem. 277 (2002) 19374-19381
21. Bradbeer J.N., Arlot M.E., Meunier P.J., and Reeve J. Treatment of osteoporosis with parathyroid peptide (hPTH 1-34) and oestrogen: increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone. Clin. Endocrinol. (Oxf.) 37 (1992) 282-289
22. Wronski T.J., Pun S., and Liang H. Effects of age, estrogen depletion, and parathyroid hormone treatment on vertebral cancellous wall width in female rats. Bone 25 (1999) 465-468
23. Jiang Y., Zhao J.J., Mitlak B.H., Wang O., Genant H.K., and Eriksen E.F. Recombinant human parathyroid hormone [1-34] [teriparatide] improves both cortical and cancellous bone structure. J. Bone Miner. Res. 18 (2003) 1932-1941
24. Burr D.B., Hirano T., Turner C.H., Hotchkiss C., Brommage R., and Hock J.M. Intermittently administered human parathyroid hormone [1-34] treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J. Bone Miner. Res. 16 (2001) 157-165
25. Hock J.M. Stemming bone loss by suppressing apoptosis. J. Clin. Invest. 104 (1999) 371-373
26. Tintut Y., Parhami F., Le V., Karsenty G., and Demer L.L. Inhibition of osteoblast-specific transcription factor Cbfa1 by the AMPc pathway in osteoblastic cells. Ubiquitin/proteasome-dependent regulation. J. Biol. Chem. 274 (1999) 28875-28879
27. Bellido T., Ali A.A., Plotkin L.I., Fu Q., Gubrij I., Roberson P.K., et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J. Biol. Chem. 278 (2003) 50259-50272
28. Calvi L.M., Sims N.A., Hunzelman J.L., Knight M.C., Giovannetti A., Saxton J.M., et al. Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J. Clin. Invest. 107 (2001) 277-286
29. Ishizuya T., Yokose S., Hori M., Noda T., Suda T., Yoshiki S., et al. Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J. Clin. Invest. 99 (1997) 2961-2970
30. Locklin R.M., Khosla S., Turner R.T., and Riggs B.L. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J. Cell. Biochem. 89 (2003) 180-190
31. Miao D., He B., Jiang Y., Kobayashi T., Soroceanu M.A., Zhao J., et al. Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J. Clin. Invest. 115 (2005) 2402-2411
32. Isogai Y., Akatsu T., Ishizuya T., Yamaguchi A., Hori M., Takahashi N., et al. Parathyroid hormone regulates osteoblast differentiation positively or negatively depending on the differentiation stages. J. Bone Miner. Res. 11 (1996) 1384-1393
33. Kream B.E., Rowe D.W., Gworek S.C., and Raisz L.G. Parathyroid hormone alters collagen synthesis and procollagen mRNA levels in fetal rat calvaria. Proc. Natl. Acad. Sci. USA 77 (1980) 5654-5658
34. Partridge N.C., Dickson C.A., Kopp K., Teitelbaum S.L., Crouch E.C., and Kahn A.J. Parathyroid hormone inhibits collagen synthesis at both ribonucleic acid and protein levels in rat osteogenic sarcoma cells. Mol. Endocrinol. 3 (1989) 232-239
35. Noda M., and Rodan G.A. Transcriptional regulation of osteopontin production in rat osteoblast-like cells by parathyroid hormone. J. Cell Biol. 108 (1989) 713-718
36. Yang R., and Gerstenfeld L.C. Signal transduction pathways mediating parathyroid hormone stimulation of bone sialoprotein gene expression in osteoblasts. J. Biol. Chem. 271 (1996) 29839-29846
37. Onyia J.E., Bidwell J., Herring J., Hulman J., and Hock J.M. In vivo, human parathyroid hormone fragment (hPTH 1-34) transiently stimulates immediate early response gene expression, but not proliferation, in trabecular bone cells of young rats. Bone 17 (1995) 479-484
38. Wang Y.H., Liu Y., Buhl K., and Rowe D.W. Comparison of the action of transient and continuous PTH on primary osteoblast cultures expressing differentiation stage-specific GFP. J. Bone Miner. Res. 20 (2005) 5-14
39. Bellido T., Ali A.A., Gubrij I., Plotkin L.I., Fu Q., O'Brien C.A., et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146 (2005) 4577-4583
40. Hofbauer L.C., and Heufelder A.E. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J. Clin. Endocrinol. Metab. 85 (2000) 2355-2363
41. Suda T., Udagawa N., and Takahashi N. Cells of bone: osteoclast generation. In: Bilezikian J.P., Raisz L.G., and Rodan G.A. (Eds). Principles of bone biology (1996), Academic Press, New York, NY, USA 87-102
42. Ma Y.L., Cain R.L., Halladay D.L., Yang X., Zeng Q., Miles R.R., et al. Catabolic effects of continuous human PTH [1-38] in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142 (2001) 4047-4054
43. Onyia J.E., Miles R.R., Yang X., Halladay D.L., Hale J., Glasebrook A., et al. In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. J. Bone Miner. Res. 15 (2000) 863-871
44. Koh A.J., Demiralp B., Neiva K.G., Hooten J., Nohutcu R.M., Shim H., et al. Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone. Endocrinology 146 (2005) 4584-4596
45. Sato M., Westmore M., Clendenon J., Smith S., Hannum B., Zeng G.Q., et al. Three-dimensional modeling of the effects of parathyroid hormone on bone distribution in lumbar vertebrae of ovariectomized cynomolgus macaques. Osteoporos. Int. 11 (2000) 871-880
46. Zhang L., Takahashi H.E., Inoue J., Tanizawa T., Endo N., Yamamoto N., et al. Effects of intermittent administration of low dose human PTH(1-34) on cancellous and cortical bone of lumbar vertebral bodies in adult beagles. Bone 21 (1997) 501-506
47. Mosekilde L., Sogaard C.H., Danielsen C.C., and Torring O. The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH-(1-34) and hPTH-(1-84). Endocrinology 129 (1991) 421-428
48. Dempster D.W., Cosman F., Kurland E.S., Zhou H., Nieves J., Woelfert L., et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J. Bone Miner. Res. 16 (2001) 1846-1853
49. Hodsman A.B., and Steer B.M. Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: evidence for de novo bone formation on quiescent cancellous surfaces. Bone 14 (1993) 523-527
50. Hock J.M., Hummert J.R., Boyce R., Fonseca J., and Raisz L.G. Resorption is not essential for the stimulation of bone growth by hPTH-(1-34) in rats in vivo. J. Bone Miner. Res. 4 (1989) 449-458
51. Zhou H., Iida-Klein A., Lu S.S., Ducayen-Knowles M., Levine L.R., Dempster D.W., et al. Anabolic action of parathyroid hormone on cortical and cancellous bone differs between axial and appendicular skeletal sites in mice. Bone 32 (2003) 513-520
52. Qi H., Li M., and Wronski T.J. A comparison of the anabolic effects of parathyroid hormone at skeletal sites with moderate and severe osteopenia in aged ovariectomized rats. J. Bone Miner. Res. 10 (1995) 948-955
53. Khosla S. Parathyroid hormone plus alendronate-a combination that does not add up. N. Engl. J. Med. 349 (2003) 1277-1279
54. Black D.M., Greenspan S.L., Ensrud K.E., Palermo L., McGowan J.A., Lang T.F., et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. 349 (2003) 1207-1215
55. Finkelstein J.S., Hayes A., Hunzelman J.L., Wyland J.J., Lee H., and Neer R.M. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N. Engl. J. Med. 349 (2003) 1216-1226
56. Sato M., Vahle J., Schmidt A., Westmore M., Smith S., Rowley E., et al. Abnormal bone architecture and biomechanical properties with near-lifetime treatment of rats with PTH. Endocrinology 143 (2002) 3230-3242
57. Sato M., Ma Y.L., Hock J.M., Westmore M.S., Vahle J., Villanueva A., et al. Skeletal efficacy with parathyroid hormone in rats was not entirely beneficial with long-term treatment. J. Pharmacol. Exp. Ther. 302 (2002) 304-313
58. Sato M., Westmore M., Ma Y.L., Schmidt A., Zeng Q.Q., Glass E.V., et al. Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity. J. Bone Miner. Res. 19 (2004) 623-629
59. Sato M., Westmore M., Clendenon J., Smith S., Hannum B., Zeng G.Q., et al. Three-dimensional modeling of the effects of parathyroid hormone on bone distribution in lumbar vertebrae of ovariectomized cynomolgus macaques. Osteoporos. Int. 11 (2000) 871-880
60. Arlot M., Meunier P.J., Boivin G., Haddock L., Tamayo J., Correa-Rotter R., et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J. Bone Miner. Res. 20 (2005) 1244-1253
61. Zanchetta J.R., Bogado C.E., Ferretti J.L., Wang O., Wilson M.G., Sato M., et al. Effects of teriparatide [recombinant human parathyroid hormone [1-34]] on cortical bone in postmenopausal women with osteoporosis. J. Bone Miner. Res. 18 (2003) 539-543
62. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone [1-34] on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344 (2001) 1434-1441
63. Misof B.M., Roschger P., Cosman F., Kurland E.S., Tesch W., Messmer P., et al. Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J. Clin. Endocrinol. Metab. 88 (2003) 1150-1156
64. Paschalis E.P., Burr D.B., Mendelsohn R., Hock J.M., and Boskey A.L. Bone mineral and collagen quality in humeri of ovariectomized cynomolgus monkeys given rhPTH [1-34] for 18 months. J. Bone Miner. Res. 18 (2003) 769-775
65. Paschalis E.P., Glass E.V., Donley D.W., and Eriksen E.F. Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial. J. Clin. Endocrinol. Metab. 90 (2005) 4644-4649
66. Rittmaster R.S., Bolognese M., Ettinger M.P., Hanley D.A., Hodsman A.B., Kendler D.L., et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J. Clin. Endocrinol. Metab. 85 (2000) 2129-2134
67. Lindsay R., Nieves J., Formica C., Henneman E., Woelfert L., Shen V., et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350 (1997) 550-555
68. Kurland E.S., Cosman F., McMahon D.J., Rosen C.J., Lindsay R., and Bilezikian J.P. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J. Clin. Endocrinol. Metab. 85 (2000) 3069-3076
69. Marcus R., Wang O., Satterwhite J., and Mitlak B. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J. Bone Miner. Res. 18 (2003) 18-23
70. Hodsman A.B., Fraher L.J., Ostbye T., Adachi J.D., and Steer B.M. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J. Clin. Invest. 91 (1993) 1138-1148
71. Lane N.E., Sanchez S., Modin G.W., Genant H.K., Pierini E., and Arnaud C.D. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J. Clin. Invest. 102 (1998) 1627-1633
72. Cosman F., Nieves J., Woelfert L., Formica C., Gordon S., Shen V., et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J. Bone Miner. Res. 16 (2001) 925-1003
73. Orwoll E.S., Scheele W.H., Paul S., Adami S., Syversen U., Diez-Perez A., et al. The effect of teriparatide (human parathyroid hormone [1-34]) therapy on bone density in men with osteoporosis. J. Bone Miner. Res. 18 (2003) 9-17
74. McClung M.R., San Martin J., Miller P.D., Civitelli R., Bandeira F., Omizo M., et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch. Intern. Med. 165 (2005) 1762-1768
75. Chen P., Satterwhite J.H., Licata A.A., Lewiecki E.M., Sipos A.A., Misurski D.M., et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J. Bone Miner. Res. 20 (2005) 962-970
76. Gowen M., Stroup G.B., Dodds R.A., James I.E., Votta B.J., Smith B.R., et al. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J. Clin. Invest. 105 (2000) 1595-1604